Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

IOVA | Iovance Biotherapeutics Inc

IndexRUT P/E- EPS (ttm)-2.25 Insider Own19.33% Shs Outstand247.78M Perf Week-22.93%
Market Cap1.13B Forward P/E- EPS next Y-1.43 Insider Trans11.68% Shs Float199.89M Perf Month-24.84%
Income-418.83M PEG- EPS next Q-0.45 Inst Own73.97% Short Float / Ratio15.04% / 4.88 Perf Quarter-39.31%
Sales0.24M P/S4718.14 EPS this Y24.47% Inst Trans-2.04% Short Interest30.07M Perf Half Y-17.36%
Book/sh2.57 P/B1.77 EPS next Y24.09% ROA-61.23% Target Price24.55 Perf Year-54.53%
Cash/sh1.01 P/C4.51 EPS next 5Y- ROE-79.68% 52W Range4.41 - 10.41 Perf YTD-28.48%
Dividend- P/FCF- EPS past 5Y-11.99% ROI-64.59% 52W High-56.10% Beta0.14
Dividend %- Quick Ratio2.99 Sales past 5Y0.00% Gross Margin-10221.01% 52W Low3.63% ATR0.47
Employees503 Current Ratio3.10 Sales Q/Q- Oper. Margin-179988.66% RSI (14)33.02 Volatility7.76% 7.47%
OptionableYes Debt/Eq0.14 EPS Q/Q24.87% Profit Margin-175981.09% Rel Volume1.75 Prev Close4.87
ShortableYes LT Debt/Eq0.12 EarningsAug 08 AMC Payout- Avg Volume6.16M Price4.57
Recom1.31 SMA20-20.09% SMA50-30.38% SMA200-33.61% Volume10,772,562 Change-6.16%
Date Action Analyst Rating Change Price Target Change
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Jun-10-21Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Sep-22-23 06:25PM
Sep-15-23 04:20PM
Sep-14-23 06:10PM
11:30AM Loading…
Sep-07-23 11:30AM
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Aug-08-23 05:50PM
Jul-31-23 06:10AM
04:01PM Loading…
Jul-25-23 04:01PM
Jul-24-23 04:01PM
Jul-21-23 05:34PM
Jul-13-23 04:01PM
Jul-11-23 04:30PM
Jul-10-23 09:46PM
Jun-24-23 03:19PM
Jun-20-23 07:01AM
Jun-16-23 08:39AM
07:01AM Loading…
Jun-15-23 07:01AM
Jun-09-23 07:01AM
Jun-08-23 11:30AM
May-30-23 04:18PM
May-29-23 10:08AM
May-26-23 05:30PM
May-24-23 12:03PM
May-16-23 09:25AM
May-11-23 01:40PM
May-10-23 12:16PM
May-09-23 04:01PM
May-02-23 04:01PM
May-01-23 04:00PM
Apr-24-23 07:01AM
Apr-20-23 09:45AM
Apr-06-23 07:22AM
Mar-30-23 11:30AM
Mar-27-23 03:56PM
Mar-24-23 04:01PM
Mar-21-23 05:10PM
Mar-04-23 08:13AM
Mar-02-23 09:17PM
Mar-01-23 12:33PM
Feb-28-23 04:01PM
Feb-27-23 09:31AM
Feb-21-23 04:01PM
Jan-24-23 12:15PM
Jan-23-23 06:37PM
Dec-16-22 09:54AM
Dec-11-22 07:23AM
Nov-30-22 07:00AM
Nov-21-22 12:11PM
Nov-18-22 01:06PM
Nov-12-22 08:34AM
Nov-10-22 12:33PM
Nov-07-22 08:01AM
Nov-04-22 12:31PM
Nov-03-22 04:01PM
Oct-27-22 07:19PM
Oct-24-22 04:01PM
Oct-11-22 11:49AM
Oct-10-22 07:30AM
Oct-05-22 09:45AM
Sep-12-22 07:00AM
Sep-06-22 04:01PM
Aug-26-22 01:13PM
Aug-25-22 01:05PM
Aug-05-22 12:13PM
Aug-04-22 04:01PM
Jul-27-22 07:00AM
Jul-22-22 05:15PM
Jun-22-22 10:48AM
Jun-17-22 05:15PM
Jun-13-22 04:01PM
Jun-12-22 09:00AM
Jun-08-22 04:01PM
Jun-06-22 08:34PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCPEAK MERRILL ADirectorSep 18Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
BILINSKY IGORChief Operating OfficerJul 14Option Exercise0.002,813028,608Jul 17 06:21 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14Option Exercise0.0020,834081,701Jul 17 06:22 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 14Option Exercise0.002,812030,930Apr 18 05:49 PM
Vogt Frederick GInterim CEO & General CounselApr 14Option Exercise0.0020,834069,718Apr 18 05:50 PM
BILINSKY IGORChief Operating OfficerApr 14Option Exercise0.002,812027,190Apr 18 05:48 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 17Option Exercise0.0011,248032,796Jan 19 04:52 PM
BILINSKY IGORChief Operating OfficerJan 17Option Exercise0.0011,248029,049Jan 19 04:52 PM
Vogt Frederick GInterim CEO & General CounselJan 17Option Exercise0.0083,325085,325Jan 19 04:51 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 03Option Exercise0.0019,690032,571Jan 05 08:57 PM
BILINSKY IGORChief Operating OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
Bellemin Jean-MarcChief Financial OfficerJan 03Option Exercise0.0018,850028,354Jan 05 08:45 PM
MCPEAK MERRILL ADirectorDec 21Buy6.1510,00061,50070,150Dec 22 04:06 PM
Rothbaum Wayne P.DirectorDec 02Buy6.5010,000,00065,000,00018,067,333Dec 02 05:29 PM
MCPEAK MERRILL ADirectorNov 29Buy6.3110,00063,100238,633Nov 30 04:17 PM
MCPEAK MERRILL ADirectorNov 28Buy6.1810,00061,800228,633Nov 28 09:44 PM
Vogt Frederick GInterim CEO & General CounselNov 28Buy5.981,0005,9802,000Nov 28 09:46 PM
Dukes Iain D.DirectorNov 23Buy6.1010,00061,00022,000Nov 28 09:43 PM